Compare XBP & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBP | AYTU |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 10200 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 27.4M |
| IPO Year | N/A | 2015 |
| Metric | XBP | AYTU |
|---|---|---|
| Price | $2.58 | $2.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $9.33 |
| AVG Volume (30 Days) | 7.0K | ★ 25.1K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | $2.59 | N/A |
| Revenue Next Year | $5.75 | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.41 | $1.65 |
| 52 Week High | $8.55 | $3.07 |
| Indicator | XBP | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 47.27 |
| Support Level | $2.07 | $2.08 |
| Resistance Level | $2.72 | $2.32 |
| Average True Range (ATR) | 0.21 | 0.10 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 50.79 | 42.32 |
XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. The segments of the company are Applied Workflow Automation and Technology. The Applied Workflow Automation segment generates maximum revenue and provides services powered by intelligent, AI-enabled workflows that generate outcomes for client's systems, while the Technology segment focuses on the sale of recurring and perpetual software licenses, software maintenance and professional services, as well as hardware solutions and maintenance.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.